Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain

Elena Galve-Calvo,1 Eva González-Haba,2 Joana Gostkorzewicz,3 Irene Martínez,4 Alejandro Pérez-Mitru4 1Medical Oncology Service, Basurto University Hospital, Bilbao, Spain; 2Pharmacy Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; 3Novartis Farmacéutica, S.A., Health Economics an...

Full description

Saved in:
Bibliographic Details
Main Authors: Galve-Calvo E (Author), González-Haba E (Author), Gostkorzewicz J (Author), Martínez I (Author), Pérez-Mitru A (Author)
Format: Book
Published: Dove Medical Press, 2018-11-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items